-
公开(公告)号：US20120258072A1
公开(公告)日：2012-10-11
申请号：US13278757
申请日：2011-10-21
IPC分类号： C07K19/00 , A61P7/02 , A61P1/00 , C12N5/10 , C12P21/02 , C12N15/63 , C12N1/19 , A61K38/20 , C12N15/62
CPC分类号： A61K38/38 , A61K38/2073 , C07K14/5431 , C07K14/76 , C07K14/765 , C07K2319/31 , Y02A50/473
摘要： The invention relates to proteins comprising Interleukin 11 (IL-11) (including, but not limited to, fragments and variants thereof), which exhibit thrombopoietic or anti-inflammatory properties, fused to albumin (including, but not limited to, fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention”. These fusion proteins exhibit extended shelf-life and/or pharmacokinetic properties and/or extended or therapeutic activity. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for treatment or prophylaxis of thrombocytopenia or inflammatory diseases.
摘要翻译： 本发明涉及包含白细胞介素11（IL-11）（包括但不限于其片段和变体）的蛋白质，其表现出与白蛋白融合的血小板生成或抗炎特性（包括但不限于片段或变体 的白蛋白）。 这些融合蛋白在本文中统称为白蛋白融合蛋白。 这些融合蛋白具有延长的保质期和/或药代动力学性质和/或延长或治疗活性。 本发明包括治疗性白蛋白融合蛋白，组合物，药物组合物，制剂和试剂盒。 本发明还包括编码本发明的白蛋白融合蛋白的核酸分子，以及含有这些核酸的载体，用这些核酸和载体转化的宿主细胞，以及使用这些核酸制备本发明的白蛋白融合蛋白的方法， 载体和/或宿主细胞。 本发明还涉及用于治疗或预防血小板减少症或炎性疾病的组合物和方法。
-
公开(公告)号：US20100143973A1
公开(公告)日：2010-06-10
申请号：US12626107
申请日：2009-11-25
IPC分类号： C07K19/00 , C12P21/00 , C12N5/10 , C12N1/21 , C12N1/15 , C12N1/19 , C12N15/63 , C07H21/04 , C07K14/54
CPC分类号： A61K38/38 , A61K38/2073 , C07K14/5431 , C07K14/76 , C07K14/765 , C07K2319/31 , Y02A50/473
摘要： The invention relates to proteins comprising Interleukin 11 (IL-11) (including, but not limited to, fragments and variants thereof), which exhibit thrombopoietic or anti-inflammatory properties, fused to albumin (including, but not limited to, fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention”. These fusion proteins exhibit extended shelf-life and/or pharmacokinetic properties and/or extended or therapeutic activity. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for treatment or prophylaxis of thrombocytopenia or inflammatory diseases.
摘要翻译： 本发明涉及包含白细胞介素11（IL-11）（包括但不限于其片段和变体）的蛋白质，其表现出与白蛋白融合的血小板生成或抗炎特性（包括但不限于片段或变体 的白蛋白）。 这些融合蛋白在本文中统称为“本发明的白蛋白融合蛋白”。 这些融合蛋白具有延长的保质期和/或药代动力学性质和/或延长或治疗活性。 本发明包括治疗性白蛋白融合蛋白，组合物，药物组合物，制剂和试剂盒。 本发明还包括编码本发明的白蛋白融合蛋白的核酸分子以及含有这些核酸的载体，用这些核酸和载体转化的宿主细胞，以及使用这些核酸制备本发明的白蛋白融合蛋白的方法 ，载体和/或宿主细胞。 本发明还涉及用于治疗或预防血小板减少症或炎性疾病的组合物和方法。
-
搜索结果
2 条记录 (耗时 0.027 秒)
